Adicet Bio Announces First Systemic Sclerosis (SSc)Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

Phase 1 clinical trial of ADI-001 in autoimmune diseases actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc

Preliminary clinical data from Phase 1 trial of ADI-001 in autoimmune diseases expected in 2H/2025

Excerpt from the Press Release:

REDWOOD CITY, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first systemic sclerosis (SSc) patient has been dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.

“We are pleased with the continued momentum of our Phase 1 trial of ADI-001 in autoimmune diseases as we announce the dosing of the first SSc patient, a key development milestone for Adicet,” said Julie Maltzman, M.D., Chief Medical Officer of Adicet Bio. “There remains a critical unmet need for safe and effective treatment options to combat debilitating autoimmune diseases, including SSc, for which we believe ADI-001 has the potential to offer transformative benefits. We are pleased with the enrollment in our LN and SLE cohort and look forward to sharing preliminary clinical data from the trial in the second half of 2025.”

About ADI-001

ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting B-cells via an anti-CD20 CAR. ADI-001 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of relapsed/refractory class III or class IV lupus nephritis (LN), refractory systemic lupus erythematosus (SLE) with extrarenal involvement and systemic sclerosis (SSc).

Click the button below to read the entire Press Release:

Continue Reading The Press Release